Clinical trial to evaluate the safety of Temsirolimus combined with Vincristine and Irinotecan in children with recurrent/refractory solid tumors
Phase 1
- Conditions
- childhood recurrent/refractory solid malignant tumors
- Registration Number
- JPRN-UMIN000017453
- Lead Sponsor
- atural Center for Basic Research and Development, Hiroshima University
- Brief Summary
This study was ended becasue the objected cases were enrolled and no DLTs appeared. The safety of dose of temsirolimus (35 mg/m2) with the combination of Vincristin and Irrinotecan was confirmed.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 3
Inclusion Criteria
Not provided
Exclusion Criteria
active double cancer severe infection abnormal ECG findings intestinal pneumonia etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Dose limiting toxicity of temusirolimus with the combination therapy of vincristin and irinotecan
- Secondary Outcome Measures
Name Time Method Response rates and adverse eventsin vincristin/irinotecan/temusirolimus combination study